CN112546195A - Safflower polypeptide light tablet - Google Patents

Safflower polypeptide light tablet Download PDF

Info

Publication number
CN112546195A
CN112546195A CN202011485883.1A CN202011485883A CN112546195A CN 112546195 A CN112546195 A CN 112546195A CN 202011485883 A CN202011485883 A CN 202011485883A CN 112546195 A CN112546195 A CN 112546195A
Authority
CN
China
Prior art keywords
safflower
polypeptide
carthamin
light tablet
linoleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011485883.1A
Other languages
Chinese (zh)
Inventor
刘袭文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202011485883.1A priority Critical patent/CN112546195A/en
Publication of CN112546195A publication Critical patent/CN112546195A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a safflower polypeptide light tablet which is prepared from the following raw materials in percentage by mass: 28-32% of white kidney bean, 48-52% of conjugated linoleic acid, 1-2% of vitamin C, 4-5% of sorbitol, 0.1-0.2% of adhesive, 2-3% of excipient, 1-2% of coating agent, 7-9% of safflower polypeptide and 2-4% of carthamin. According to the safflower polypeptide light tablet, the ingredients such as white kidney beans, conjugated linoleic acid, vitamin C, safflower polypeptide, carthamin and the like are added into a weight-reducing product, so that the product has a weight-reducing effect and is more comprehensive in nutrition; the safflower polypeptide can rapidly provide nutrition for immune cells, stimulate the activity of the immune cells, improve the immunity of the organism, regulate the state of the organism, and ensure the health and stability of the organism, so that diseases caused by the immune system are relieved; in addition, safflower polypeptide can regulate endocrine of body, thereby relieving diseases caused by endocrine disturbance.

Description

Safflower polypeptide light tablet
Technical Field
The invention relates to the technical field of medicines and health-care products, in particular to a safflower polypeptide light tablet.
Background
The weight-losing products on the market at present mainly comprise weight-losing medicines, meal-replacing foods and the like, and the main principle of the weight-losing medicines is that the appetite is reduced by controlling the brain diet control center, and people can become addicted by long-term or large-scale eating, and symptoms such as hallucination, tension, insomnia, palpitation, nervousness and the like appear; the meal replacement food meets the group requirements of young people on beauty and pressure relief no matter in consideration of health and slimming or in response to the demand of fast pace of life, but many products on the market at present have single formula and do not meet the intention of meal replacement, and the state has no mandatory standard for the emerging market. Now that the food is called as meal replacement food, a more systematic and comprehensive nutritional formula is required, but many meal replacement products on the market at present cannot meet the requirement. Eating the meal only every day can not meet the basic metabolic demand of the human body, and long-term eating can cause the symptoms of physical weakness, hypodynamia, dizziness and the like of people, and even can cause endocrine disturbance and gastrointestinal inflammation, and female amenorrhea, organ degeneration and the like. Therefore, there is a need to develop a nutritionally complete weight loss product.
Disclosure of Invention
In view of the above technical problems in the related art, the present invention provides a light safflower polypeptide tablet (tablet containing safflower extract) which can overcome the above disadvantages of the prior art.
In order to achieve the technical purpose, the technical scheme of the invention is realized as follows:
the safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
28-32% of white kidney bean, 48-52% of conjugated linoleic acid, 1-2% of vitamin C, 4-5% of sorbitol, 0.1-0.2% of adhesive, 2-3% of excipient, 1-2% of coating agent, 7-9% of safflower polypeptide and 2-4% of carthamin.
Preferably, the safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
30% of white kidney bean, 50% of conjugated linoleic acid, 1.9% of vitamin C, 5% of sorbitol, 0.1% of binder, 2% of excipient, 1% of coating agent, 7.0% of safflower polypeptide and 3.0% of carthamin.
Preferably, the binder is acacia gum.
Preferably, the excipient is magnesium stearate.
Preferably, the coating agent is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose and polyvinylpyrrolidone.
The white kidney beans have rich nutritive value and high medicinal and health-care values, are traditional medicinal and edible foods in China, have good adjuvant therapy effect and many efficacies and effects; the starch blocking food is a natural starch blocking food, is rich in alpha-amylase inhibitor and dietary fiber, can be effectively matched with diet therapy of weight-losing people to ensure that the people eat fully and eliminate hunger sensation without high postprandial blood sugar and weight increase, can effectively block the decomposition of starch in high-starch foods (rice, wheaten food, coarse cereals, related snacks and cakes), blocks the intake of most of starch calories, and reduces the maximum fat source of human bodies. Moreover, the alpha-amylase inhibitor is discharged out of the body through the gastrointestinal tract, does not need to pass through blood circulation, does not act on the nervous center of the brain, does not cause diarrhea, hypodynamia, anorexia and weight rebound after being eaten, and completely accords with the weight-losing principle of the world health organization. The kidney bean is also a high-potassium low-sodium food, and is very suitable for patients with heart disease, arteriosclerosis, hyperlipidemia and salt-contraindication.
Human clinical trials prove that conjugated linoleic acid can effectively reduce the fat content in the body and the ratio of fat to muscle. According to a paper published in journal of Lipids, 2007 in month 7, 20 healthy volunteers were tested by norwegian scientists with an average body weight of 156 pounds, each test group taking 3,500 capsules per day, with body fat decreasing from 21.3 to 17, control group increasing from 22.0 to 22.4, test group decreasing from 156.6 to 154.4 pounds, control group decreasing from 158.9 to 159.4 pounds. The Conjugated Linoleic Acid (CLA) capsule is tested by human body test of health supervision and inspection institute of Ministry of public health of the people's republic of China for 60 days, and the following conclusion is obtained: the average body weight was reduced by 1.9 kg and the total fat by 1.2 kg, which is clearly different from the pre-test (p90), and the blood pressure was reduced to normal after the test, and the experiments showed that the CLA weight-reducing effect was more significant when the conjugated linoleic acid capsules were used for physical exercise, and probably was the most difficult food to reduce the weight. CLA reduces the belly, the abdomen most prone to fat accumulation during exercise and least likely to migrate into the stomach, so the large abdomen is most annoying to both men and women. Conjugated linoleic acid can convert body fat into lean meat, and if proper exercise can be performed, the stomach can be operated more easily. Conjugated linoleic acid is well suited for persons who want body building.
One of the reasons for the weight loss of conjugated linoleic acid is that conjugated linoleic acid can be oxidized to change cell permeability, so that fat and glucose can pass through the cell membrane of muscle more easily, and energy is generated to meet the demand of human body, so that fat cells are excreted and utilized. Lipoprotein lipase can deposit fat in the body, conjugated linoleic acid can reduce fat by reducing the activity of lipoprotein lipase, and can increase the activity of fat burning lipase, change the ratio of muscle to fat, reduce abdominal fat and increase muscle mass.
The invention has the beneficial effects that: according to the safflower polypeptide light tablet, the ingredients such as white kidney beans, conjugated linoleic acid, vitamin C, safflower polypeptide, carthamin and the like are added into a weight-reducing product, so that the product has a weight-reducing effect and is more comprehensive in nutrition;
the safflower polypeptide can rapidly provide nutrition for immune cells, stimulate the activity of the immune cells, improve the immunity of the organism, regulate the state of the organism, and ensure the health and stability of the organism, so that diseases caused by the immune system are relieved; in addition, the safflower polypeptide can regulate the endocrine of the body, thereby relieving diseases caused by endocrine dyscrasia;
carthamin is a water-soluble flavonoid compound, is mostly stored in flower buds of plant safflower, can be purified to obtain a freeze-dried preparation, has the functions of promoting blood circulation and removing blood stasis, can promote blood circulation and regulate menstruation, and also has obvious treatment effect on amenorrhea, incomplete postpartum lochiorrhea, abdominal pain and other adverse symptoms; carthamin can dredge channels and collaterals, has certain therapeutic effect on various adverse symptoms such as limb pain and apoplexy caused by obstructed channels and collaterals, and can relieve rheumatism osteodynia, numbness of limbs and lumbar muscle strain symptoms; the carthamin has certain protection effect on skin, can prevent pigment from silting, relieve measles and color spots caused by heat stagnation, prevent skin color from deepening, and has certain beautifying effect when taken in proper amount; in addition, carthamin can dilate blood vessels, accelerate blood circulation, prevent platelets from coagulating into blocks, increase the dissolving capacity of fibrin in a human body, reduce blood viscosity and prevent hypertension and hyperlipidemia when taken in proper amount; besides the above effects, carthamin can protect human cardiovascular and brain, and can delay human aging;
the kidney bean has sweet taste, has the functions of warming middle-jiao and lower-jiao, benefiting intestines and stomach, stopping hiccup, tonifying kidney, supplementing primordial qi and the like, is a good nourishing food therapy product, also has a calming effect, has certain curative effect on deficiency-cold hiccup, stomach cold vomiting, traumatic injury, asthma cough, lumbago and neuralgia, in addition, kidney bean granules contain various globulins such as hemagglutinin and the like, can not only agglomerate red blood cells of a human body, activate embryonic transformation of lymphocytes, promote mitosis, increase deoxyribonucleic acid and synthesis thereof, inhibit immune reaction and movement of white blood cells and lymphocytes, but also activate lymphocytes of a tumor patient to generate lymphotoxin and have the effect of relieving specific injury to various animal cells, so the kidney bean has obvious tumor regression effect, and the components such as saponin, urase, various globulins and the like contained in the kidney bean can improve the self-immunity of the human body, the kidney bean can also stimulate the hematopoietic function of bone marrow, enhance the anti-infection ability of patients, induce the proliferation of osteoblasts and promote the healing of fracture.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments given herein are intended to be within the scope of the present invention.
Example 1
The safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
30% of white kidney bean, 50% of conjugated linoleic acid, 1.9% of vitamin C, 5% of sorbitol, 0.1% of binder, 2% of excipient, 1% of coating agent, 7% of safflower polypeptide and 3.0% of carthamin.
Wherein the adhesive is acacia, the excipient is magnesium stearate, and the coating agent is hydroxypropyl methylcellulose.
Example 2
The safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
28% of white kidney bean, 52% of conjugated linoleic acid, 1% of vitamin C, 4% of sorbitol, 0.2% of binder, 3% of excipient, 1% of coating agent, 7% of safflower polypeptide and 3.8% of carthamin.
Wherein the adhesive is acacia, the excipient is magnesium stearate, and the coating agent is polyvinylpyrrolidone.
Example 3
The safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
32% of white kidney bean, 48% of conjugated linoleic acid, 1% of vitamin C, 4% of sorbitol, 0.1% of binder, 2% of excipient, 2% of coating agent, 8.9% of safflower polypeptide and 2% of carthamin.
Wherein the adhesive is acacia, the excipient is magnesium stearate, and the coating agent is hydroxypropyl cellulose.
In conclusion, by means of the technical scheme, the ingredients such as white kidney beans, conjugated linoleic acid, vitamin C, safflower polypeptide, carthamin and the like are added into the weight-losing product, so that the product has a weight-losing effect and is more comprehensive in nutrition;
the safflower polypeptide can rapidly provide nutrition for immune cells, stimulate the activity of the immune cells, improve the immunity of the organism, regulate the state of the organism, and ensure the health and stability of the organism, so that diseases caused by the immune system are relieved; in addition, the safflower polypeptide can regulate the endocrine of the body, thereby relieving diseases caused by endocrine dyscrasia;
carthamin is a water-soluble flavonoid compound, is mostly stored in flower buds of plant safflower, and can be purified to obtain a freeze-dried preparation; the carthamin has the effects of promoting blood circulation, removing blood stasis, promoting blood circulation, regulating menstruation, and treating amenorrhea, puerperal lochiorrhea, abdominal pain, etc.; carthamin can dredge channels and collaterals, has certain therapeutic effect on various adverse symptoms such as limb pain and apoplexy caused by obstructed channels and collaterals, and can relieve rheumatism osteodynia, numbness of limbs and lumbar muscle strain symptoms; the carthamin has certain protection effect on skin, can prevent pigment from silting, relieve measles and color spots caused by heat stagnation, prevent skin color from deepening, and has certain beautifying effect when taken in proper amount; in addition, carthamin can dilate blood vessels, accelerate blood circulation, prevent platelets from coagulating into blocks, increase the dissolving capacity of fibrin in a human body, reduce blood viscosity and prevent hypertension and hyperlipidemia when taken in proper amount; besides the above effects, carthamin can protect human cardiovascular and brain, and can delay human aging;
the kidney bean has sweet taste, has the functions of warming middle-jiao and lower-jiao, benefiting intestines and stomach, stopping hiccup, tonifying kidney, supplementing primordial qi and the like, is a good nourishing food therapy product, also has a calming effect, has certain curative effect on deficiency-cold hiccup, stomach cold vomiting, traumatic injury, asthma cough, lumbago and neuralgia, in addition, kidney bean granules contain various globulins such as hemagglutinin and the like, can not only agglomerate red blood cells of a human body, activate embryonic transformation of lymphocytes, promote mitosis, increase deoxyribonucleic acid and synthesis thereof, inhibit immune reaction and movement of white blood cells and lymphocytes, but also activate lymphocytes of a tumor patient to generate lymphotoxin and have the effect of relieving specific injury to various animal cells, so the kidney bean has obvious tumor regression effect, and the components such as saponin, urase, various globulins and the like contained in the kidney bean can improve the self-immunity of the human body, the kidney bean can also stimulate the hematopoietic function of bone marrow, enhance the anti-infection ability of patients, induce the proliferation of osteoblasts and promote the healing of fracture.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (5)

1. The safflower polypeptide light tablet is characterized by being prepared from the following raw materials in percentage by mass:
28-32% of white kidney bean, 48-52% of conjugated linoleic acid, 1-2% of vitamin C, 4-5% of sorbitol, 0.1-0.2% of adhesive, 2-3% of excipient, 1-2% of coating agent, 7-9% of safflower polypeptide and 2-4% of carthamin.
2. The safflower polypeptide light tablet of claim 1, wherein the safflower polypeptide light tablet is prepared from the following raw materials in percentage by mass:
30% of white kidney bean, 50% of conjugated linoleic acid, 1.9% of vitamin C, 5% of sorbitol, 0.1% of binder, 2% of excipient, 1% of coating agent, 7.0% of safflower polypeptide and 3.0% of carthamin.
3. The safflower polypeptide light tablet of claim 1, wherein the binding agent is gum arabic.
4. The safflower polypeptide light tablet of claim 1, wherein the excipient is magnesium stearate.
5. The safflower polypeptide light tablet of claim 1, wherein the coating agent is one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, and polyvinylpyrrolidone.
CN202011485883.1A 2020-12-16 2020-12-16 Safflower polypeptide light tablet Pending CN112546195A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011485883.1A CN112546195A (en) 2020-12-16 2020-12-16 Safflower polypeptide light tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011485883.1A CN112546195A (en) 2020-12-16 2020-12-16 Safflower polypeptide light tablet

Publications (1)

Publication Number Publication Date
CN112546195A true CN112546195A (en) 2021-03-26

Family

ID=75064013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011485883.1A Pending CN112546195A (en) 2020-12-16 2020-12-16 Safflower polypeptide light tablet

Country Status (1)

Country Link
CN (1) CN112546195A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850065A (en) * 2005-04-23 2006-10-25 中山市尤利卡天然药物有限公司 Use of oral conjugated linoleic acid and its derivative for increasing muscule and skin beauty
CN104630317A (en) * 2014-10-13 2015-05-20 石河子大学 Method for preparing safflower seed antioxidant peptide
CN112118855A (en) * 2018-03-20 2020-12-22 爱瑟金股份有限公司 Weight management composition
CN112402325A (en) * 2020-12-18 2021-02-26 刘袭文 Safflower polypeptide reverse-aging cream

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850065A (en) * 2005-04-23 2006-10-25 中山市尤利卡天然药物有限公司 Use of oral conjugated linoleic acid and its derivative for increasing muscule and skin beauty
CN104630317A (en) * 2014-10-13 2015-05-20 石河子大学 Method for preparing safflower seed antioxidant peptide
CN112118855A (en) * 2018-03-20 2020-12-22 爱瑟金股份有限公司 Weight management composition
CN112402325A (en) * 2020-12-18 2021-02-26 刘袭文 Safflower polypeptide reverse-aging cream

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHUXIN2018: "白芸豆的功效有哪些，有什么副作用和禁忌？", 《M.XUETANGZAIXIAN.COM/ZHONGYAO/16062.HTML》 *
GM63: "多肽的功效与作用", 《WWW.360DOC.COM/CONTENT/20/0526/20/841137_914715588.SHTML》 *
孙立，等: "红花籽抗氧化肽的分离纯化及抗氧化活性研究", 《农产品加工（学刊）》 *
果蔬网: "红花素的功效与作用 红花素的副作用", 《HTTPS://WWW.CHINAFRUITS.CN/ZHONGYAO/79040-HONGHUASUDEGONGXIAOYUZUOYONG.HTML》 *
美容美体网: "【共轭亚油酸】为什么说共轭亚油酸减肥效果明显？", 《HTTPS://M.ILIFE.CN/ZHUANTI/CLA/17300.HTML》 *

Similar Documents

Publication Publication Date Title
CN107173694A (en) A kind of full vegetarian diet meal replacement powder formula of comprehensive nutrition balance
CN108142803A (en) Full nutrition coarse food grain
CN106213501A (en) A kind of nutrition soup and preparation method thereof
CN103355544A (en) Lactation sow forage
CN106418545A (en) Functional food with balanced nutrients
CN112137115A (en) Ketogenic nutrition powder with immunity enhancing effect and preparation method thereof
CN103610144A (en) Walnut powder with blood glucose reduction effect and preparation method thereof
EP1198994B1 (en) Health food products
CN106418501A (en) Healthcare food with weight reducing function
CN111771988A (en) Nutritional food suitable for diabetic patients and preparation method thereof
CN107897908A (en) A kind of breakfast suitable for weight-reducing reconstitutes food therapeutic composition and preparation method thereof
CN103007107B (en) Chinese medicinal preparation for regulating postpartum frail
CN105249440A (en) Donkey-hide gelatin cake
CN111184214A (en) Enzyme collagen coarse cereal, fruit and vegetable instant meal replacement porridge and making method thereof
CN103704568B (en) Clinic dietary food
CN112155159A (en) Preparation method of health flour
Awulachew The role of wheat in human nutrition and its medicinal value
CN107950862A (en) A kind of red date jelly and preparation method thereof
KR20180011985A (en) Kyungokgo and manufacturing method of the same
CN105341704A (en) Brown sugar red bean paste
CN101991110A (en) Wild ganoderma lucidum food
CN112546195A (en) Safflower polypeptide light tablet
CN112137098A (en) Public health breakfast powder and preparation method thereof
CN106035686A (en) Super chenopodium quinoa willd health-preservation plant milk
Amudha et al. Rice-a novel food with medicinal value

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210326

RJ01 Rejection of invention patent application after publication